CLINICAL CASE O THE EFFECTIVE TREATMENT OF RELAPSE OF ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA WITH BRAF V600E MUTATION USING TARGET DRUG VEMURAFENIB

Pleomorphic xanthoastrocytomas are rare glial tumors. They account for less than 1% of the cerebral astrocytomas. Pleomorphic xanthoastrocytomas are low-grade glial tumors, namely, 2nd grade according to WHO classification. In some cases, however, anaplastic pleomorphic xanthoastrocytomas may develop, and they are characterized by a more aggressive course, frequent relapses, like high-grade cerebral gliomas brain (anaplastic astrocytoma or glioblastoma). BRAF V600 mutation in tumor occurs in 30-40% of cases of anaplastic pleomorphic xanthoastrocytoma. Presented clinical case demonstrates the ability to achieve long-term remission using B-raf inhibitor vemurafenib in the treatment of patient with relapses of anaplastic pleomorphic xanthoastrocytoma and with the V600E BRAF mutation in tumor. It is necessary to conduct clinical studies of BRAF inhibitors in patients with anaplastic pleomorphic xanthoastrocytomas with the presence of BRAF V600 mutations in tumor.

pleomorphic xanthoastrocytomas, V600 BRAF mutation in tumor, vemurafenib